GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
J

Jeil Pharma Holdings 002620.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

6,900

+1.47%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Jeil Pharma Holdings

Its shares trade on KRX under the ticker 002620.KS. It has been listed since 20 January 1988. In the fiscal year to 31 December 2025, it reported revenue of ₩657.61bn and net income of ₩14.64bn. At that date it held total assets of ₩876.66bn and shareholders' equity of ₩318.74bn.

Jeil Pharma Holdings, Inc. engages in the management of its subsidiaries. The company is headquartered in Seoul, Seoul. The firm provides antibiotics, anti-inflammatory painkillers, hepatitis remedies, duodenum ulcer treatments, anticancer drugs, tristimania drugs, gastritis drugs, stomach ulcer drugs, septicemia treatments, pollakisuria treatments, acute bronchitis remedies, hyperlipidemia treatments and others. The firm distributes its products within domestic market and to overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
20 Jan 1988

Leadership

Pay as last reported

  • Mr. Sang Cheol HanPresident, Chief Executive Officer, Director, since 2010
  • Mr. Bong Hui MoonVice President, Director
  • Mr. Byeong Gu SeoAssistant Managing Director
  • Ms. Ju Hyeon LeeDirector
  • Mr. Seung Bae JeonNon-Executive Independent Director
  • Mr. Dong Yeol LeeNon-Executive Independent Director
  • Mr. Gi Bong ParkNon-Executive Independent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Seoul, South Korea
  • Provides a diverse range of pharmaceutical products including antibiotics and anticancer drugs
  • Distributes products domestically and internationally

Weaknesses

  • No specific weaknesses mentioned in the provided information
  • No information on market share or financial performance
  • No details on competitive advantages or unique selling points

Opportunities

  • Expansion into overseas markets for pharmaceutical products
  • Growth potential in the health care sector
  • Diversification of product portfolio beyond current offerings

Threats

  • Competition from other pharmaceutical companies
  • Regulatory challenges in the pharmaceutical industry
  • Dependence on domestic market for a portion of revenue

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.